Outcomes in Bone Giant Cell Tumors Treated With Surgical Resection With and Without Denosumab Injection: A Single-Institution Retrospective Study

医学 德诺苏马布 外科 骨巨细胞瘤 刮除术 回顾性队列研究 巨细胞 骨质疏松症 内分泌学 病理
作者
Ali H AlYami,Abdulaziz Nazer,Hussam H Bashawieh,Albara A Dabroom,Majd Saem Aldahar,AlWaleed A AlYami,Bandar N AlMaeen
出处
期刊:Cureus [Cureus, Inc.]
标识
DOI:10.7759/cureus.26869
摘要

Background: Giant cell tumors of the bone (GCTB) are rare, benign, aggressive, recurrent tumors that are most often found at the ends of long bones. They account for 5% of all primary bone tumors and 20% of all benign bone tumors. The clinical features of GCTB include local swelling, pain, and limitations in joint movement. Approximately half of GCTB arise around the knee joint, affecting either the distal femur or proximal tibia. Tissue biopsy reveals an excess of multinucleated giant cells on a stromal cell background, indicating a diagnosis. Intralesional curettage is used to treat GCTB and is associated with minimal disability; however, local recurrence may occur in many patients. Resection and endoprosthetic repair or bone graft reconstruction are often used to treat GCTB near the joint. To our knowledge, there are currently no studies on this topic in the city of Jeddah, where we conducted our study. Our aim was to evaluate the outcome of surgical resection accompanied by denosumab injection compared to that of surgery alone in treating GCTB. Methods: All cases of GCTB at King Abdulaziz Medical City, Jeddah, between January 2008 and December 2018, that fulfilled the inclusion and exclusion criteria were included. All cases of GCTB in the pre-specified period were classified as surgical resection with denosumab injection or surgical resection alone. The outcomes of the two modalities were compared. Recurrence was investigated in patients belonging to both the groups. Results: Twenty-six cases that met the inclusion criteria were included in the study and the data were analyzed. The subjects were divided into two groups: denosumab and surgery (n = 7) and surgery alone (n = 19). Patients treated with denosumab and surgery had a higher recurrence rate (57%); however, the difference was not significant (p = 0.407). Conclusion: Our study showed that when comparing local recurrence after curettage in patients treated with denosumab and patients who did not receive it, preoperative denosumab therapy was associated with an increased incidence of local recurrence. We recommend a systematic review that can include more studies in this field to acquire more definitive results regarding this topic.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不回首完成签到 ,获得积分10
8秒前
俭朴的世界完成签到 ,获得积分10
11秒前
士萧完成签到,获得积分10
13秒前
lyon完成签到 ,获得积分10
15秒前
小星星完成签到,获得积分10
17秒前
duoduo完成签到,获得积分10
17秒前
昏睡的胖粘完成签到 ,获得积分10
17秒前
even完成签到 ,获得积分10
17秒前
压缩完成签到 ,获得积分10
19秒前
时尚雨兰完成签到,获得积分10
19秒前
棒棒完成签到 ,获得积分10
20秒前
茅十八完成签到,获得积分10
20秒前
lin完成签到 ,获得积分10
21秒前
蓝莓酱完成签到,获得积分10
22秒前
科研小白完成签到 ,获得积分10
23秒前
成就的书包完成签到 ,获得积分10
25秒前
dldldl完成签到,获得积分10
31秒前
简隋英完成签到 ,获得积分10
32秒前
悦悦完成签到,获得积分10
33秒前
牛人完成签到,获得积分10
33秒前
yuan完成签到,获得积分10
35秒前
deswin完成签到 ,获得积分10
37秒前
海山了完成签到,获得积分10
38秒前
39秒前
娟娟完成签到 ,获得积分10
40秒前
露卡完成签到,获得积分10
47秒前
Borw完成签到 ,获得积分10
49秒前
新风完成签到,获得积分10
49秒前
cctv18应助忧郁的火车采纳,获得10
59秒前
石破天惊完成签到,获得积分10
1分钟前
1分钟前
634301059完成签到 ,获得积分10
1分钟前
邬戎完成签到,获得积分10
1分钟前
kin完成签到 ,获得积分10
1分钟前
柯一一应助强健的冰旋采纳,获得10
1分钟前
如意烨霖完成签到,获得积分10
1分钟前
rgjipeng完成签到,获得积分10
1分钟前
小夏完成签到 ,获得积分10
1分钟前
uan完成签到,获得积分10
1分钟前
刘企盼完成签到,获得积分10
1分钟前
高分求助中
Sraffa and applied economics: are there classical supply curves? 1000
Heun’s Differential Equations 600
《Fundamentals of Power Supply Design》Robert A. Mammano 510
谁能看见前面有梦可想 500
Wind Effects on Structures: An Introduction to Wind Engineering and Wind Forces in Engineering (2nd Edition) 300
High Wire: How China Regulates Big Tech and Governs Its Economy 260
lingnan science journal vol. 16 250
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2249308
求助须知:如何正确求助?哪些是违规求助? 1898426
关于积分的说明 4734329
捐赠科研通 1687755
什么是DOI,文献DOI怎么找? 856267
版权声明 545258
科研通“疑难数据库(出版商)”最低求助积分说明 453190